Latest News on SIGA

Financial News Based On Company


Advertisement
Advertisement

Weekly Recap: SIGA Q3 financial results and Canada TPOXX contract

https://www.tradingview.com/news/tradingview:0614c301daf4b:0-weekly-recap-siga-q3-financial-results-and-canada-tpoxx-contract/
SIGA Technologies Inc. (NASDAQ:SIGA) reported Q3 2026 revenue of $1.3 million and a net loss of $2.9 million, with no product sales following its final U.S. contract delivery in Q2. The company secured a five-year oral TPOXX contract with Canada valued at up to $15 million, including $9 million committed. SIGA also delayed its supplemental TPOXX application for post-exposure prevention to 2028 due to FDA-requested work and is in late-stage talks for another international contract.

SIGA Technologies, Inc. (SIGA) Seasonal returns chart

https://au.finance.yahoo.com/quote/SIGA/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for SIGA Technologies, Inc. (SIGA). It displays the average monthly price return for the company's stock between 2016 and 2026. The article also includes current stock performance data and navigation to other financial information for SIGA.

SIGA Technologies 3Q 2026: Revenue $1.32M, EPS ($0.04) — 10-Q Summary

https://www.tradingview.com/news/tradingview:9db0f0f888061:0-siga-technologies-3q-2026-revenue-1-32m-eps-0-04-10-q-summary/
SIGA Technologies reported a third-quarter 2026 revenue of $1.32 million, a 49.7% year-over-year decrease, while its net loss narrowed to ($2.89 million) from ($6.37 million) in the prior year. The company's diluted EPS improved to ($0.04) from ($0.09). Key factors included reduced research and development activity, lower manufacturing technology transfer costs, and decreased billable activities under the BARDA contract, though BARDA added $2.1 million for regulatory activities, and a new contract for up to $15 million was awarded by the Canadian DND for oral TPOXX® purchases.

SIGA Technologies | 10-Q: Q3 2026 Earnings Report

https://www.moomoo.com/news/notice/1004038153/quarterly-report
This document is the 10-Q filing for SIGA Technologies, detailing their earnings report for the third quarter of 2026. It provides a comprehensive overview of the company's financial performance and operational status during that period.

SIGA (SIGA) Q3 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/8746386/siga-siga-q3-2026-earnings-call-transcript/
SIGA Technologies reported its Q3 and nine-month 2026 financial results, completing its BARDA 19C contract obligations. The company is now focused on securing a new U.S. government procurement contract, though the timing is uncertain. SIGA also announced a new five-year contract with the Canadian Department of National Defence and is in advanced negotiations for another international agreement.
Advertisement

SIGA Technologies Inc (SIGA) (Q3 2026) Earnings Call Highlights: New Canada Contract, $116 ...

https://ca.finance.yahoo.com/news/siga-technologies-inc-siga-q3-070856558.html
SIGA Technologies Inc (SIGA) reported its Q3 2026 earnings, highlighting a new five-year contract with Canada's Department of National Defense for oral TPOXX, valued up to $15 million. While the company secured approximately $42 million in product revenue for the first nine months of 2026 and maintains a strong cash balance of $116 million with no debt, it experienced a pre-tax operating loss of $7 million and no product sales in Q3. SIGA also noted delays in securing a new US Government contract and the supplemental NDA for its post-exposure prophylaxis program, now expected in 2028.

SIGA: $42M in 9M product revenue; Canadian contract secured as U.S. award timing remains uncertain

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4542869:0-siga-42m-in-9m-product-revenue-canadian-contract-secured-as-u-s-award-timing-remains-uncertain/
SIGA Technologies (SIGA) reported nine-month product revenue of $42 million, with no sales in Q3, and ended the quarter with $116 million in cash and no debt. The company secured a five-year Canadian contract worth up to $15 million. However, the timing of U.S. procurement remains uncertain, and the PEP filing has been delayed to 2028.

SIGA Technologies, Inc. (SIGA) Reports Q3 Loss of $0.04

https://www.streetinsider.com/Earnings/SIGA+Technologies%2C+Inc.+%28SIGA%29+Reports+Q3+Loss+of+%240.04/27315931.html
SIGA Technologies, Inc. (NASDAQ: SIGA) announced a Q3 EPS loss of ($0.04), with revenue for the quarter reported at $1.3 million. The company's financial fact included a loss before benefit from income taxes of -9.25M. This report provides key financial figures for the third quarter.

Canada awards SIGA a contract for up to about $15 million of oral smallpox medicine

https://www.stocktitan.net/news/SIGA/siga-reports-financial-results-for-three-and-nine-months-ended-46vr478njsyl.html
SIGA Technologies announced that the Canadian Department of National Defence awarded it a contract for up to $15 million worth of oral TPOXX, with $9 million in firm commitments over the first three years. This contract contributes to SIGA's international business strategy amidst ongoing efforts to secure new procurement contracts with the U.S. government. The company also reported a narrower net loss for the third quarter of 2026, though its nine-month revenue significantly decreased compared to the prior year.

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026

https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/siga-reports-financial-results-for-three-and-nine-months-ended-september-30-2026/2465675
SIGA Technologies, Inc. (SIGA) reported its financial results for the three and nine months ended September 30, 2026, highlighting a $15 million procurement contract from the Canadian Department of National Defence for oral TPOXX. CEO Diem Nguyen emphasized the importance of international business while pursuing new U.S. Government contracts. The company also announced the retirement of its Chief Scientific Officer, Dennis Hruby, Ph.D.
Advertisement

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

https://www.globenewswire.com/news-release/2026/11/09/3398916/9738/en/siga-announces-retirement-of-chief-scientific-officer-dennis-hruby-ph-d.html
SIGA Technologies (NASDAQ: SIGA) announced the retirement of Dennis Hruby, Ph.D., Executive Vice President and Chief Scientific Officer, effective November 9, 2026, after more than 30 years with the company. Dr. Hruby led the development of TPOXX®, the first FDA-approved antiviral for smallpox, through its various regulatory approvals. He will continue to support SIGA in an advisory capacity post-retirement.

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026

https://www.globenewswire.com/news-release/2026/11/09/3398911/0/en/siga-reports-financial-results-for-three-and-nine-months-ended-september-30-2026.html
SIGA Technologies, Inc. reported financial results for the three and nine months ended September 30, 2026, highlighting a $15 million procurement contract from the Canadian Department of National Defence for oral TPOXX. The company's total revenues for the nine months decreased to $48.6 million from $90.8 million in the prior year, with a net income of $6.1 million compared to $28.7 million in 2025. SIGA also announced the retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026

https://www.globenewswire.com/news-release/2026/11/09/3398911/9738/en/siga-reports-financial-results-for-three-and-nine-months-ended-september-30-2026.html
SIGA Technologies, Inc. reported its financial results for the three and nine months ended September 30, 2026, highlighting a $15 million procurement contract from the Canadian Department of National Defence for oral TPOXX. While working towards a new U.S. government contract, the company emphasized the importance of its international business and efforts to diversify its customer base. The report also detailed financial figures, operational activities including TPOXX deliveries, and the retirement of Chief Scientific Officer Dennis Hruby.

Lobbying Update: $100,000 of SIGA TECHNOLOGIES INC. lobbying was just disclosed

https://www.quiverquant.com/news/Lobbying+Update%3A+%24100%2C000+of+SIGA+TECHNOLOGIES+INC.+lobbying+was+just+disclosed
A new Lobbying Disclosure Act filing reveals that SIGA Technologies Inc. disclosed $100,000 in lobbying expenditures for Q3 2026, focusing on "Antiviral treatment, medical countermeasure and bioterrorism matters." This comes as 93 institutional investors increased their positions in SIGA stock, while 81 decreased theirs in the most recent quarter, with BlackRock Inc. and FIRST WILSHIRE SECURITIES MANAGEMENT INC. making notable additions.

SIGA Technologies, Inc. (SIGA) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/SIGA/
This page provides an overview of SIGA Technologies, Inc. (SIGA) stock, including its real-time price, historical data, and various financial metrics. As of October 30, the stock was trading at $3.04, down 4.40%, with after-hours trading showing a further slight decrease. The page also offers sections for news, charts, community insights, and valuation measures.
Advertisement

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

https://finance.yahoo.com/healthcare/articles/siga-host-business-call-november-113000844.html
SIGA Technologies, Inc. (Nasdaq: SIGA) announced it will host a webcast and conference call on Monday, November 9, 2026, at 4:30 P.M. ET to provide a business update after releasing its third-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A replay will be available for two weeks following the call.

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

https://www.moomoo.com/news/post/1002820301/siga-to-host-business-update-call-on-november-9-2026
SIGA Technologies (SIGA) will host a business update call on November 9, 2026, to discuss its third-quarter 2026 financial results. The call will follow the release of these results and provide an overview of the company's performance and future outlook.

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/10/29/3391154/9738/en/siga-to-host-business-update-call-on-november-9-2026-following-release-of-third-quarter-2026-financial-results.html
SIGA Technologies, Inc. announced it will host a webcast and conference call on Monday, November 9, 2026, at 4:30 P.M. ET to provide a business update following the release of its third-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A replay will be available for two weeks after the event.

SIGA secures up to $15M contract to supply smallpox antiviral TPOXX to Canadian Defence.

https://pluang.com/en/news-feed/siga-mendapat-kontrak-15-juta-dari-pertahanan-kanada-untuk-pembelian-tpoxx
SIGA Technologies has secured a contract worth up to $15 million with the Canadian Department of National Defence to supply oral TPOXX, an antiviral for smallpox, through March 2031. This agreement emphasizes Canada's ongoing commitment to smallpox preparedness and ensures the Canadian Armed Forces have access to essential medical countermeasures. The contract includes $9 million in firm commitments for the initial three years and an additional $6 million in options, supporting global partnerships in infectious disease protection.

Canada awards SIGA $15M contract for smallpox treatment supply By Investing.com

https://uk.investing.com/news/stock-market-news/canada-awards-siga-15m-contract-for-smallpox-treatment-supply-93CH-4937213
SIGA Technologies has been awarded a contract by Public Services and Procurement Canada, valued at up to $15 million, for its oral TPOXX smallpox treatment. This agreement, extending through March 2031, includes firm commitments for the Canadian Department of National Defence, supporting Canada's defence industrial strategy and ensuring access to critical medical countermeasures for its armed forces. This is the second such contract, reinforcing Canada's consistent leadership in smallpox preparedness.
Advertisement

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

https://www.globenewswire.com/news-release/2026/10/28/3390052/9738/en/siga-secures-contract-valued-at-up-to-15-million-from-canadian-department-of-national-defence-to-purchase-tpoxx.html
SIGA Technologies Inc. announced a new contract with Public Services and Procurement Canada (PSPC) for the procurement of oral TPOXX®, an antiviral medication for smallpox, on behalf of the Canadian Department of National Defence (CDND). The contract is valued at up to $15 million by March 31, 2031, with $9 million as firm commitments over the first three years. This agreement continues Canada's commitment to smallpox preparedness for its armed forces and builds on a previous contract awarded in 2020.

Canada awards SIGA $15M contract for smallpox treatment supply By Investing.com

https://ng.investing.com/news/stock-market-news/canada-awards-siga-15m-contract-for-smallpox-treatment-supply-93CH-2762980
SIGA Technologies Inc. has been awarded a contract worth up to $15 million by Public Services and Procurement Canada for its oral smallpox treatment, TPOXX. This contract, extending through March 2031, includes firm commitments of $9 million over the first three years and ensures the Canadian Armed Forces have continued access to this critical antiviral medication. This marks the second such contract, reinforcing Canada's commitment to smallpox preparedness.

SIGA Wins $15 Million Canadian Defense Contract for Oral TPOXX

https://www.tokenpost.com/news/business/42654
SIGA Technologies has been awarded a $15 million contract by Public Services and Procurement Canada to provide oral TPOXX (tecovirimat) for the Canadian Department of National Defence. This procurement is part of Canada's Strategic Medical Countermeasures Program, reinforcing the country's medical defense capabilities. John Kim of TokenPost reported on the deal.

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

https://www.globenewswire.com/news-release/2026/10/28/3390052/0/en/siga-secures-contract-valued-at-up-to-15-million-from-canadian-department-of-national-defence-to-purchase-tpoxx.html
SIGA Technologies Inc. announced a new contract with Public Services and Procurement Canada (PSPC) for the procurement of oral TPOXX®, an antiviral medication for smallpox. The contract, valued at up to $15 million by March 31, 2031, will supply the Canadian Department of National Defence and continues Canada's commitment to smallpox preparedness. This marks the second TPOXX® contract for Canada, reinforcing the country's health security and defence objectives.

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

https://www.globenewswire.com/de/news-release/2026/10/28/3390052/9738/en/siga-secures-contract-valued-at-up-to-15-million-from-canadian-department-of-national-defence-to-purchase-tpoxx.html
SIGA Technologies Inc. announced a new contract with Public Services and Procurement Canada (PSPC) for the procurement of oral TPOXX®, an antiviral medication for smallpox, on behalf of the Canadian Department of National Defence. The contract is valued at up to $15 million by March 31, 2031, with firm commitments of approximately $9 million over the first three years. This marks the second contract for TPOXX® from CDND, reinforcing Canada's commitment to smallpox preparedness for its armed forces.
Advertisement

SIGA Technologies Inc. Estimates – NASDAQ:SIGA

https://www.tradingview.com/symbols/NASDAQ-SIGA/financials-estimates/
This article provides access to the financial actuals and analyst estimates for SIGA Technologies Inc. (NASDAQ: SIGA) through TradingView. Users can explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, and cash flow statements, as well as visualize trends over time. The platform explicitly states this is not investment advice and encourages users to conduct their own research.

SIGA stock: Q2 revenue reached USD 41.00 million. SIGA stock is valued at USD 224.20 million

https://www.ad-hoc-news.de/boerse/news/nebenwerte/siga-stock-q2-revenue-reached-usd-41-00-million-siga-stock-is-valued-at-usd-224-20-million/70402074
SIGA Technologies reported second-quarter revenue of USD 41.00 million, with a market capitalization of USD 224.20 million as of October 23, 2026. The company held USD 118.00 million in cash and zero debt by June 30, 2026, and is pursuing a new multi-year U.S. procurement contract after fulfilling its 19C contract. Future plans include an FDA submission for its post-exposure prophylaxis program in the first half of 2027.

SIGA targets 2027 FDA filing: what it means for SIGA stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/siga-targets-2027-fda-filing-what-it-means-for-siga-stock/70379081
SIGA Technologies is aiming for an FDA submission in the first half of 2027 for its post-exposure prophylaxis program, providing a long-term development milestone for investors. The company reported Q2 revenue of $41 million, with product-related revenue reaching $41 million for the first half of 2026, primarily from TPOXX deliveries. SIGA's next earnings report is scheduled for November 5, 2026, which will offer updated information on product deliveries and progress towards the regulatory goal.

SIGA Forecast — Price Target — Prediction for 2027

https://www.tradingview.com/symbols/NASDAQ-SIGA/forecast-price-target/?exchange=NASDAQ
This article provides a forecast and price target for SIGA Technologies Inc. (SIGA) stock. It includes analyst price estimates, historical performance data, and answers frequently asked questions about the company's financials, market capitalization, and volatility. The article highlights that one analyst offers a 1-year price forecast with a maximum and minimum estimate of $11.57.

SIGA targeted a 2027 FDA filing: what it means for SIGA stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/siga-targeted-a-2027-fda-filing-what-it-means-for-siga-stock/70334803
SIGA Technologies aims for an FDA submission in the first half of 2027 for pediatric post-exposure prophylaxis of smallpox. The company reported $38.0 million in product revenue for Q2 2026 and held $117.6 million in cash with no debt as of June 30, 2026. This regulatory milestone and the company's financial position are key factors for investors.
Advertisement

Full Transcript: SIGA Technologies Q2 2026 Earnings Call

https://www.benzinga.com/news/26/10/62296533/full-transcript-siga-technologies-q2-2026-earnings-call
SIGA Technologies reported $38 million in Q2 2026 product revenues, driven by U.S. government IV TPOXX deliveries and international sales, fulfilling its 2018 contract obligations and engaging in new procurement discussions. The company is expanding its global footprint through a distribution agreement with Hikma for the MENA region and advancing its post-exposure prophylaxis and pediatric programs, with a strong financial position of $118 million in cash. Management emphasized ongoing government partnerships and international market growth as key strategies for addressing smallpox preparedness.

SIGA Technologies stock reports USD 41.0 million Q2 revenue

https://www.ad-hoc-news.de/boerse/news/nebenwerte/siga-technologies-stock-reports-usd-41-0-million-q2-revenue/70250526
SIGA Technologies reported Q2 2026 revenue of $41.0 million, a significant decrease from $81.1 million in Q2 2025, primarily due to the timing of product deliveries and reliance on government procurement cycles. The company's management is currently negotiating a successor multiyear government contract after fulfilling its obligations under the previous 19C contract. Despite the revenue decline, SIGA maintains a strong cash position with $117.6 million and no debt, and is pursuing FDA submission for a post-exposure prophylaxis program in early 2027.

SIGA Technologies stock reports USD 41 million Q2 revenue

https://www.ad-hoc-news.de/boerse/news/corporate-news/siga-technologies-stock-reports-usd-41-million-q2-revenue/70233330
SIGA Technologies reported Q2 2026 revenue of USD 41 million, a significant rebound from Q1 but still down year-over-year. Diluted EPS fell to USD 0.17 from USD 0.49, reflecting the impact of delivery timing on profitability. The company maintains a debt-free balance sheet with USD 117.6 million in cash, and its stock closed at USD 3.38 on October 2, 2026, amid a "Sell" consensus rating.

Bank of America buys 427,275 shares in SIGA Technologies stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/bank-of-america-buys-427-275-shares-in-siga-technologies-stock/70215507
Bank of America has acquired 427,275 shares of SIGA Technologies stock, valued at $1.6 million, according to a Q2 filing. SIGA Technologies reported second-quarter revenue of $41.0 million and a net income of $12.5 million, maintaining profitability despite a year-over-year contraction in revenue and profit. The company, which has zero debt and $117.6 million in cash, is pursuing new government and international orders, with its next earnings report expected on November 5, 2026.

Siga Technologies Inc. $SIGA Shares Newly Purchased by Bank of America Corp DE

https://www.marketbeat.com/instant-alerts/filing-siga-technologies-inc-siga-shares-newly-purchased-by-bank-of-america-corp-de-2026-10-02/
Bank of America Corp DE recently acquired 427,275 shares of Siga Technologies Inc. (NASDAQ:SIGA), valued at approximately $1.56 million, making up about 0.59% of the company. Other institutional investors like BlackRock and Dimensional Fund Advisors also increased their stakes, with institutions and hedge funds collectively owning 55.4% of SIGA. Despite the institutional interest, the company's shares opened at $3.35, significantly below its 52-week high, and MarketBeat reports an average analyst rating of “Sell.”
Advertisement

Promising Penny Stocks To Watch In September 2026

https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/promising-penny-stocks-to-watch-in-september-2026
This article highlights promising penny stocks to watch in September 2026, focusing on companies with strong balance sheets and solid fundamentals. It profiles SIGA Technologies (SIGA), OPKO Health (OPK), and UP Fintech Holding (TIGR), detailing their financial health, operations, recent performance, and future outlook. The article emphasizes that while penny stocks offer growth opportunities, investors should conduct thorough research.

SIGA Technologies stock holds value as small cap metrics guide investors

https://www.ad-hoc-news.de/boerse/news/nebenwerte/siga-technologies-stock-holds-value-as-small-cap-metrics-guide-investors/70154308
SIGA Technologies' stock performance is closely tied to its small-cap profile and operating figures rather than broad market trends. The article emphasizes that investors should focus on reported revenue, net income, earnings per share, and product demand to assess the company's valuation. While Nasdaq index movements provide a market reference, they do not offer specific catalysts for this specialized biotechnology stock.

SIGA: SIGA Technologies Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/SIGA
The article provides the latest stock price and sentiment for SIGA Technologies Inc. (SIGA), showing a stock price of $3.52 with a 1.15% increase pre-market. It also includes a user's question regarding the timing of a potential new contract for SIGA, pending efficacy proof in other pox viruses.

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

https://finance.yahoo.com/markets/stocks/articles/siga-tech-siga-profits-drop-124131686.html
SIGA Technologies reported a significant drop in revenue and profits for the recent quarter and first half of the year compared to the previous year, with net income falling by 65%. This decline is largely attributed to the completion of a major government contract (19C) for TPOXX sales. Despite the downturn, the company remained profitable and issued a special cash dividend, while also expanding international and alternative stockpile orders.

BlackRock Inc. Makes New $15.24 Million Investment in Siga Technologies Inc. $SIGA

https://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-1524-million-investment-in-siga-technologies-inc-siga-2026-09-04/
BlackRock Inc. has invested $15.24 million in Siga Technologies Inc., acquiring 4.19 million shares, representing a 5.84% stake. Despite this new investment, analyst sentiment for Siga Technologies remains negative, with the stock downgraded to "sell" and a consensus "Sell" rating. The company reported quarterly revenue of $41 million and earnings per share of $0.17, but continues to show negative profitability metrics.
Advertisement

Siga Technologies (NASDAQ:SIGA) Shares Up 2.6% - Should You Buy?

https://www.marketbeat.com/instant-alerts/price-siga-technologies-nasdaq-siga-shares-up-26-should-you-buy-2026-08-31/
Siga Technologies (NASDAQ:SIGA) shares rose 2.6% in Monday trading, but analyst sentiment remains negative with a "Sell" rating. The company reported quarterly EPS of $0.17 on $41 million revenue, though profitability was weak. Institutional investors have recently adjusted their holdings in the specialty pharmaceutical company.

Siga Technologies (SIGA) Earnings Date and Reports 2026

https://www.marketbeat.com/stocks/NASDAQ/SIGA/earnings/
Siga Technologies (SIGA) reported Q2 2026 earnings on August 6, 2026, with an EPS of $0.17 and quarterly revenue of $41 million. The company's next earnings date is estimated for November 5, 2026, after market close, based on historical reporting schedules. This report provides historical earnings data and upcoming estimates for investors.

Identiv Leads The Charge In These 3 Promising Penny Stocks

https://www.sahmcapital.com/news/content/identiv-leads-the-charge-in-these-3-promising-penny-stocks-2026-08-19
This article highlights three promising penny stocks: Identiv (INVE), SIGA Technologies (SIGA), and Emergent BioSolutions (EBS), based on their financial health and market potential. While each company faces unique challenges like unprofitability or declining revenue, they also demonstrate strengths such as strong cash positions, no debt, or significant contracts. The analysis emphasizes that penny stocks can offer growth opportunities for investors despite their inherent risks.

Identiv Leads The Charge In These 3 Promising Penny Stocks

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/identiv-leads-the-charge-in-these-3-promising-penny-stocks
This article identifies three promising penny stocks: Identiv (INVE), SIGA Technologies (SIGA), and Emergent BioSolutions (EBS), highlighting their financial health and market potential. Identiv, despite losses, shows strong cash and no debt, while SIGA Technologies operates debt-free and is undervalued. Emergent BioSolutions, though unprofitable with high debt, maintains a strong cash runway and secured significant contracts.

SIGA Technologies Inc (SIGA) Earnings Forecast: Future EPS & Revenue Growth Estimates

https://www.tradingkey.com/markets/stocks/siga/forecast
The article provides an earnings forecast for SIGA Technologies Inc (SIGA), detailing estimated future EPS, revenue, net
Advertisement

SIGA Technologies (SIGA) Stock Slips As Contract Uncertainty Trumps Profit

https://www.sahmcapital.com/news/content/siga-technologies-siga-stock-slips-as-contract-uncertainty-trumps-profit-2026-08-08
SIGA Technologies (SIGA) reported a profit in Q2 2026, but its stock still slipped due to contract uncertainty and declining revenue and EPS compared to the previous year. Despite a strong cash balance and no debt, the market is concerned about the volatility of TPOXX sales, which depend on a small group of government buyers with unpredictable procurement cycles. This has led to a significant drop in the stock over the past three months.

Siga Technologies Q2 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:37332053b094b:0-siga-technologies-q2-earnings-call-highlights/
Siga Technologies reported strong Q2 product-related revenue of $38 million, primarily from TPOXX sales to the U.S. Strategic National Stockpile and international customers. The company completed its 19C contract for IV TPOXX delivery to the U.S. government and is in discussions for a new multiyear procurement contract. SIGA also continues to pursue international sales opportunities and advance its TPOXX pipeline programs, including post-exposure prophylaxis and pediatric formulations.

Siga Technologies Q2 Earnings Call Highlights

https://www.marketbeat.com/instant-alerts/siga-technologies-q2-earnings-call-highlights-2026-08-07/
Siga Technologies reported $38 million in Q2 product revenue, driven by TPOXX sales to the U.S. Strategic National Stockpile and international customers, resulting in a net income of $12 million. The company is in ongoing discussions for a new multiyear TPOXX procurement agreement with the U.S. government, despite delays due to leadership changes within HHS. SIGA is also prioritizing international expansion and pipeline development, including a potential FDA submission for TPOXX in early 2027.

SIGA TECHNOLOGIES INC 2Q 2026: Revenue $41M, EPS $0.17— 10-Q Summary

https://www.tradingview.com/news/tradingview:01428e6411ae9:0-siga-technologies-inc-2q-2026-revenue-41m-eps-0-17-10-q-summary/
SIGA TECHNOLOGIES INC reported its Q2 2026 results with revenue of $41 million and diluted earnings per share of $0.17, both significantly down from the prior-year quarter due to shifts in product mix and lower U.S. oral TPOXX® deliveries. The company's business remains heavily reliant on U.S. government procurements, though international sales showed an increase. Regulatory updates included the removal of the mpox indication for its product in Europe while retaining approvals for other conditions.

SIGA Technologies Inc (SIGA) (Q2 2026) Earnings Call Highlights: Strong Revenue and Strategic ...

https://finance.yahoo.com/healthcare/articles/siga-technologies-inc-siga-q2-051039557.html
SIGA Technologies Inc (SIGA) reported strong Q2 2026 product-related revenues of $38 million, driven by US Strategic National Stockpile deliveries and international sales. The company is diversifying its customer base and has a strong balance sheet with $118 million in cash and no debt. Despite these positives, SIGA faces delays in securing a new multi-year contract with the US government and uncertainty regarding future TPOXX deliveries and international procurement decisions.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement